BRPI0708278B8 - forma cristalina "a" do sal de arginina de perindopril, seu uso, processo para sua preparação e composição farmacêutica - Google Patents

forma cristalina "a" do sal de arginina de perindopril, seu uso, processo para sua preparação e composição farmacêutica

Info

Publication number
BRPI0708278B8
BRPI0708278B8 BRPI0708278A BRPI0708278A BRPI0708278B8 BR PI0708278 B8 BRPI0708278 B8 BR PI0708278B8 BR PI0708278 A BRPI0708278 A BR PI0708278A BR PI0708278 A BRPI0708278 A BR PI0708278A BR PI0708278 B8 BRPI0708278 B8 BR PI0708278B8
Authority
BR
Brazil
Prior art keywords
perindopril
preparation
crystalline form
arginine salt
pharmaceutical composition
Prior art date
Application number
BRPI0708278A
Other languages
English (en)
Inventor
Coquerel Gérard
Souvie Jean-Claude
Lefebvre Löic
Authouart Pascale
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37022969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0708278(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of BRPI0708278A2 publication Critical patent/BRPI0708278A2/pt
Publication of BRPI0708278B1 publication Critical patent/BRPI0708278B1/pt
Publication of BRPI0708278B8 publication Critical patent/BRPI0708278B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

forma cristalina alfa do sal arginina do perindopril, o respectivo processo de preparação, e as composições farmacêuticas que a contêm. a presente invenção refere-se a uma forma cristalina a do composto de fórmula (i), caracterizada por seu diagrama de difração x sobre pó. medicamentos.
BRPI0708278A 2006-02-28 2007-02-26 forma cristalina "a" do sal de arginina de perindopril, seu uso, processo para sua preparação e composição farmacêutica BRPI0708278B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0601748 2006-02-28
FR0601748A FR2897866B1 (fr) 2006-02-28 2006-02-28 Forme cristalline alpha du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
PCT/FR2007/000335 WO2007099217A1 (fr) 2006-02-28 2007-02-26 FORME CRISTALLINE α DU SEL D'ARGININE DU PERINDOPRIL, SON PROCEDE DE PREPARATION, ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT

Publications (3)

Publication Number Publication Date
BRPI0708278A2 BRPI0708278A2 (pt) 2011-05-24
BRPI0708278B1 BRPI0708278B1 (pt) 2021-03-02
BRPI0708278B8 true BRPI0708278B8 (pt) 2021-05-25

Family

ID=37022969

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0708278A BRPI0708278B8 (pt) 2006-02-28 2007-02-26 forma cristalina "a" do sal de arginina de perindopril, seu uso, processo para sua preparação e composição farmacêutica

Country Status (28)

Country Link
US (1) US7846961B2 (pt)
EP (1) EP1989182B1 (pt)
JP (1) JP5255454B2 (pt)
KR (2) KR20120001818A (pt)
CN (1) CN101389603B (pt)
AU (1) AU2007220435B2 (pt)
BR (1) BRPI0708278B8 (pt)
CA (1) CA2644467C (pt)
CY (1) CY1117753T1 (pt)
DK (1) DK1989182T3 (pt)
EA (1) EA014716B1 (pt)
ES (1) ES2581982T3 (pt)
FR (1) FR2897866B1 (pt)
GE (1) GEP20125433B (pt)
HK (1) HK1129669A1 (pt)
HR (1) HRP20160644T1 (pt)
HU (1) HUE027898T2 (pt)
MA (1) MA30276B1 (pt)
ME (1) ME02456B (pt)
MY (1) MY151035A (pt)
NO (1) NO20083535L (pt)
NZ (1) NZ570367A (pt)
PL (1) PL1989182T3 (pt)
RS (1) RS54754B1 (pt)
SI (1) SI1989182T1 (pt)
UA (1) UA89905C2 (pt)
WO (1) WO2007099217A1 (pt)
ZA (1) ZA200807024B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2318365B1 (en) 2008-06-24 2015-08-12 Mylan Laboratories Limited Novel polymorphic forms of perindopril (l)-arginine and process for the preparation thereof
AU2009212902A1 (en) 2008-09-03 2010-03-18 Apotex Pharmachem Inc. Amorphous form of an L-arginine salt of perindopril and processes of preparation thereof
SI23149A (sl) 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
FR2985511B1 (fr) * 2012-01-05 2014-01-03 Servier Lab Forme cristalline delta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2985512B1 (fr) * 2012-01-05 2014-06-20 Servier Lab Procede de preparation du sel de l-arginine du perindopril
CN103172696B (zh) * 2012-12-19 2014-12-17 宁波美诺华药业股份有限公司 一种γ晶型的培哚普利精氨酸盐的制备方法
FR3050380B1 (fr) 2016-04-20 2020-07-10 Les Laboratoires Servier Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains.
EP3842035A1 (en) 2019-12-23 2021-06-30 KRKA, d.d., Novo mesto Composition for the preparation of perindopril arginine granules, a method for their preparation and pharmaceutical composition comprising the granules
SI26268A (sl) 2021-11-18 2023-05-31 Zupet Rok Postopek za pripravo hidratirane oblike perindopril l-arginina
CN114149357B (zh) * 2021-12-29 2024-06-25 江苏嘉逸医药有限公司 一种γ晶型培哚普利精氨酸盐的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2503155A2 (fr) * 1980-10-02 1982-10-08 Science Union & Cie Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
FR2811320B1 (fr) * 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline alpha du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2811318B1 (fr) * 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline gamma du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2811319B1 (fr) * 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline beta du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2838648B1 (fr) * 2002-04-18 2004-05-21 Servier Lab Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
FR2897865B1 (fr) 2006-02-28 2008-04-18 Servier Lab Forme cristalline beta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
EP2318365B1 (en) 2008-06-24 2015-08-12 Mylan Laboratories Limited Novel polymorphic forms of perindopril (l)-arginine and process for the preparation thereof

Also Published As

Publication number Publication date
EA200801777A1 (ru) 2009-02-27
CN101389603A (zh) 2009-03-18
CY1117753T1 (el) 2017-05-17
US7846961B2 (en) 2010-12-07
EP1989182A1 (fr) 2008-11-12
PL1989182T3 (pl) 2016-09-30
EP1989182B1 (fr) 2016-04-13
NO20083535L (no) 2008-08-14
DK1989182T3 (en) 2016-07-25
JP5255454B2 (ja) 2013-08-07
HUE027898T2 (en) 2016-10-28
ME02456B (me) 2017-02-20
AU2007220435B2 (en) 2010-11-04
GEP20125433B (en) 2012-03-26
FR2897866B1 (fr) 2008-04-18
JP2009534295A (ja) 2009-09-24
US20090203758A1 (en) 2009-08-13
KR20080106948A (ko) 2008-12-09
BRPI0708278B1 (pt) 2021-03-02
CA2644467A1 (fr) 2007-09-07
UA89905C2 (ru) 2010-03-10
CA2644467C (fr) 2011-07-26
HK1129669A1 (pt) 2009-12-04
FR2897866A1 (fr) 2007-08-31
WO2007099217A1 (fr) 2007-09-07
KR20120001818A (ko) 2012-01-04
HRP20160644T1 (hr) 2016-07-01
AU2007220435A1 (en) 2007-09-07
SI1989182T1 (sl) 2016-07-29
MY151035A (en) 2014-03-31
ZA200807024B (en) 2010-04-28
MA30276B1 (fr) 2009-03-02
EA014716B1 (ru) 2011-02-28
BRPI0708278A2 (pt) 2011-05-24
ES2581982T3 (es) 2016-09-08
RS54754B1 (sr) 2016-10-31
NZ570367A (en) 2011-03-31
CN101389603B (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
BRPI0708278B8 (pt) forma cristalina "a" do sal de arginina de perindopril, seu uso, processo para sua preparação e composição farmacêutica
BRPI0500393A (pt) Processo para a sìntese e forma cristalina de agomelatina e composições farmacêuticas contendo-a
BRPI0603059A (pt) forma cristalina v de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
BRPI0603043A (pt) forma cristalina iv de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
BRPI0600795B8 (pt) forma betad-cristalina de cloridrato de ivabradina, um processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
BRPI0600796B8 (pt) forma gama-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
ECSP088859A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
BRPI0603074A (pt) forma cristalina iii de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
BRPI0600623A (pt) forma beta-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
UY30824A1 (es) Nuevos derivados de idazolil éster o amida, composiciones farmacéuticas conteniéndolas, procesos de preparacion y aplicaciones.
GT200600086A (es) Forma cristalina de gamma-d del clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
BRPI0502228A (pt) forma cristalina alfa de ranelato de estrÈncio, processo para sua preparação, e composições farmacêuticas que a contêm
BRPI0908353B8 (pt) composto ou um sal farmaceuticamente aceitavel do mesmo e composição farmaceutica
UY31046A1 (es) Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones
BRPI0514766A (pt) composições farmacêuticas
ECSP066914A (es) FORMA CRISTALINA dd DEL CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
BR112013025881A2 (pt) composto representado pela fórmula geral (i), composto ou um sal do mesmo, inibidor deagregação tau, inibidor de b-secretase, inibidor de agregação de b-proteína amiloide, composição farmacêutica, preparação oral ou parenteral e composto representado pela fórmula geral (ii)
AR029570A1 (es) Nueva forma cristalina gamma de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
BRPI0817096B8 (pt) análogo de tiazolidinodiona e composição farmacêutica que o compreende
BR0112244A (pt) Forma cristalina beta do sal de terc-butilamina do perindopril, respectivo processo de preparação e composições farmacêuticas que a contêm
BRPI1013821A8 (pt) piridinas substituídas como antagonistas de ccr3.
BRPI0607093A2 (pt) polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil)amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende
TR201902435T4 (tr) DGAT1 inhibitör içeren farmasötik bileşimler.
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
BRPI0617180B8 (pt) processo para produção de uma mistura diretamente comprimível, formulação de ibuprofeno produzida pelo processo, e, forma de dosagem farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/02/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF